Latest Conference Articles

Using TMB and PD-L1 Together Could Guide Immunotherapy Decisions in NSCLC

Until more biomarkers are available, the use of tumor mutational burden with PD-L1 expression could help oncologists further personalize immunotherapy choices for patients with non–small cell lung cancer.

Socinski Says Immunotherapy, Targeted Therapy Have Altered Outlook in NSCLC

Mark A. Socinski, MD, provides an overview of treatment advances in the lung cancer landscape, and highlights where much-needed work still remains.

Expert Stresses Significance of Durvalumab Success in Stage III NSCLC

Findings from the PACIFIC trial have made a significant impact on the treatment of patients with unresectable stage III non–small cell lung cancer, especially in light of the history of treatment options in this setting.

Dr. Decker on Current Role of Radiation in NSCLC

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses the current role of radiation therapy in the treatment of patients with non–small cell lung cancer.

Brahmer Provides a Glimpse of Future Immunotherapeutics in NSCLC

Despite the rapidly expanding therapeutic options available in immunotherapy for patients with non-small cell lung cancer, there are still a number of drawbacks to treatment, explaining why not all patients respond to current treatment options.

Dr. Jahanzeb on Eligibility Criteria for Immunotherapy Trials in NSCLC

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the eligibility criteria for immunotherapy trials in non–small cell lung cancer.

Targeted Agents Show Promise Against Emerging Oncogenic Drivers in NSCLC

Data on many new treatment options have come forward over the past year highlighting the potential to treat more emerging oncogenic drivers impacting smaller subsets of patients with non–small cell lung cancer.

Surgery Maintains Role in Rapidly Advancing Lung Cancer Treatment Paradigm

Eric Vallieres, MD, highlights the technological advances of lung cancer surgery and how this impacts the outlook for patients who are candidates for it.

Dr. Wakelee Discusses Current State of Treatment in NSCLC

Heather Wakelee, MD, associate professor of medicine (oncology), Stanford University Medical Center, discusses the current state of treatment in patients with non–small cell lung cancer.

Dr. Goldberg Discusses Treatment Approaches for Mesothelioma

Sarah B. Goldberg, MD, MPH, an assistant professor of medicine at the Yale School of Medicine and Yale Cancer Center, discusses traditional and emerging treatment approaches for patients with mesothelioma.

Treatment Options Expand for ROS1, BRAF, and NTRK Alterations in NSCLC

A growing focus on smaller oncogenic drivers in lung cancer has opened up new treatment options and many potential drugs in development for patients with less common alterations.

EGFR-Targeted Activity Helps Differentiation Between TKIs in NSCLC

The treatment paradigm for EGFR-mutant non–small cell lung cancer has grown significantly with many EGFR TKIs now available to treat patients with this disease.

Lilenbaum Examines EGFR+ NSCLC Advancements and Potential Role of Immunotherapy

Rogerio Lilenbaum, MD, highlights the current treatment approaches for patients with EGFR-positive non–small cell lung cancer and shed light on the potential for immunotherapy in the space.

Dr. Brahmer on Managing Immune-Related AEs in Lung Cancer

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses managing immune-related adverse events in lung cancer.

Dr. Garon on Potential for Immunotherapy in EGFR+ NSCLC

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses the potential for immunotherapy in the treatment of patients with EGFR-positive non–small cell lung cancer.

Patient Selection Key to Future of Immunotherapy in Endometrioid Disease

Successful application of immunotherapy in endometrial cancer means identifying the patients with inflamed tumors who will respond to treatment and those who will not, and finding ways to treat noninflamed tumors with immunotherapy agents.

Study Supports TKI Response as Predictor of Survival in HCC

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

Dr. Strosberg Discusses Results for KEYNOTE-158

Jonathan R. Strosberg, MD, discusses the findings from the phase II KEYNOTE-158 trial investigating pembrolizumab in patients with advanced neuroendocrine tumors.

Ongoing Research to Move Needle Forward in Gynecologic Cancer Treatment

Robert Coleman, MD, highlights recent advances made in gynecologic cancers and provide insight into ongoing research to move the needle forward.

Durvalumab/Tremelimumab Combo Improves Efficacy in Refractory CRC

The combination use of durvalumab and tremelimumab plus best supportive care prolonged median overall survival by 2.5 months compared with supportive care alone in patients with advanced refractory colorectal cancer.

Single-Agent Durvalumab Elicits Responses in MSI-H CRC

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

Dr. Leath Discusses Unmet Need in Cervical Cancer

Charles A. Leath III, MD, gyn oncologist at the University of Alabama at Birmingham, discusses the glaring unmet need in cervical cancer.

Dr. Coleman on Advances Made in Ovarian Cancer Treatment

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses advances made in the treatment of ovarian cancer.

Triplet Regimen Shows Durable Responses in BRAF V600E-Mutant Metastatic CRC

Clinical outcomes with the combination of encorafenib, binimetinib, and cetuximab exceed historic data in patients with BRAF V600E-mutant metastatic colorectal cancer.

Antiangiogenics, ADCs Still Have Roles in Ovarian Cancer Treatment

For all the positive data associated with PARP inhibitors in patients with epithelial ovarian cancer who have known BRCA mutations and despite several agents winning FDA approval over the past few years, PARP inhibitors aren’t curing patients.

Regorafenib Extends PFS in Locally Advanced Biliary Tract Cancer

The oral multi-kinase inhibitor regorafenib extended progression-free survival in patients with metastatic or unresectable biliary tract cancer who were previously treated with gemcitabine and a platinum-based chemotherapy.

Westin Highlights the Evolving Role of PARP Inhibitors in Ovarian Cancer

Shannon Westin, MD, discusses the evolving role of PARP inhibitors in ovarian cancer, novel investigational agents, and the importance of molecular testing.

Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Dabrafenib/Trametinib Combo Induces High Responses in BRAF V600E-Mutant Biliary Tract Cancer

The combination of dabrafenib and trametinib induced responses in nearly half of patients with BRAF V600E–mutated biliary tract cancer who participated in a phase II basket trial that enrolled patients with BRAF V600E–mutated rare cancers.

SM-88 Achieves Encouraging Clinical Benefit Rate in Metastatic Pancreatic Cancer

The novel oral anticancer regimen known as SM-88, which consists of a tyrosine derivative, an mTOR inhibitor, a CYP3a4 inducer, and an oxidative stress catalyst, has promising efficacy with no meaningful toxicity in patients with metastatic pancreatic cancer who have progressed on at least 1 prior line of therapy.